Ficonax

Quick links to important sections

Ficonax

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ficonax

What is Ficonax?

Ficonax is a pharmacological treatment containing the active substance midostaurin. It belongs to a class of medications known as protein kinase inhibitors. These agents work by blocking the action of specific enzymes called kinases, which are involved in the signaling pathways that regulate the growth and division of cells.

Mechanism of Action

In certain conditions, specific proteins or enzymes become overactive, leading to the uncontrolled production of abnormal cells. Ficonax is designed to bind to and inhibit these signaling proteins, including the FLT3 and KIT receptors. By interfering with these pathways, the medication helps to slow down or stop the proliferation of the affected cells.

Clinical Applications

Ficonax is utilized in the management of specific hematological conditions characterized by genetic mutations or the overproduction of certain white blood cells. Its primary use cases include:

  • Acute Myeloid Leukemia (AML): Specifically for cases where a mutation in the FLT3 gene is present. In this context, it is typically integrated into a broader treatment plan alongside standard chemotherapy.
  • Systemic Mastocytosis: This includes advanced forms of the disease, such as aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia. In these instances, the medication targets the overactive KIT protein to reduce the accumulation of mast cells in the body's organs.

Purpose of Treatment

The fundamental goal of Ficonax therapy is to achieve a reduction in the number of abnormal cells and to assist in managing the progression of the underlying blood or bone marrow disorder. Because it targets specific molecular drivers of disease, it is considered a form of targeted therapy.

Regulatory References

  1. Metformin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Ficonax?

Possible Side Effects and Safety Information

The regulatory documentation for Ficonax (Metformin Hydrochloride) structures its safety profile by classifying adverse reactions according to their observed frequency and the body system affected. These official classifications detail the range of possible effects.

Common and Expected Adverse Reactions

Adverse effects affecting the gastrointestinal system are the most frequently documented reactions. These are classified as Very Common (occurring in 10% or more of patients) and include diarrhea, nausea, vomiting, and abdominal pain. Other effects classified as Common (occurring in 1% to 10% of patients) include a metallic taste disturbance, flatulence, and asthenia (weakness). Regulatory sources specify that gastrointestinal reactions are most frequently observed at the beginning of treatment and often become transient.


Serious Adverse Reactions and Population-Specific Constraints

A small number of reactions are documented as serious, though their official frequency is classified as Very Rare (less than 1 in 10,000 patients). The most significant is Lactic Acidosis, a rare but potentially fatal metabolic complication. Additionally, a decrease in Vitamin B12 serum levels is associated with long-term exposure and may, in rare instances, lead to megaloblastic anemia.

The official safety labeling contains critical population-specific constraints to mitigate the risk of Lactic Acidosis. The risk is heightened with renal dysfunction, leading to a contraindication for Ficonax in patients with severe renal impairment (estimated glomerular filtration rate ( eGFR) below 30 mL/min/1.73 m^2). The medication is generally avoided in cases of hepatic impairment. Furthermore, the consumption of excessive alcohol is noted to increase the risk of Lactic Acidosis.


Regulatory Safety Summary

The safety framework establishes that most expected reactions are common and transient, but formally highlights the Very Rare risk of serious metabolic complications. This framework mandates strict restrictions based on patient status, particularly renal function, which must be assessed frequently in groups like older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

The most serious consequence of Ficonax (Metformin Hydrochloride) overdose is Lactic Acidosis, which is officially classified as a rare but severe and potentially fatal metabolic complication resulting from drug accumulation.

Officially Documented Manifestations:

Classification Symptom/Sign (as per Regulatory Label)
Non-Specific Onset Malaise, Myalgias (muscle pain), Somnolence (drowsiness), Abdominal pain, Vomiting, Respiratory distress
Severe Outcomes Hypothermia, Hypotension, Resistant bradyarrhythmias, Coma, Death (in severe cases)
Laboratory Findings Elevated blood lactate levels (ge 5 mmol/L), Decreased blood pH (< 7.35), Anion Gap Acidosis

Required Emergency Actions

Lactic Acidosis is a medical emergency that requires immediate treatment in a hospital setting. The patient must immediately discontinue the drug and seek urgent medical attention if any symptoms suggestive of acidosis occur. Prompt Hemodialysis is recommended by regulatory agencies to correct the severe acidosis and remove the accumulated Metformin, as no specific antidote is known.

Population-Specific Risk: The risk of this life-threatening complication increases with renal impairment, advanced age (ge 65 years), and hepatic impairment, as these factors compromise the body's ability to clear the drug and lactate, leading to accumulation.

Therapeutic Uses of Ficonax

The primary therapeutic role of Ficonax is applied in addressing Type 2 Diabetes Mellitus (T2DM). The medication is commonly used as initial therapy to help regulate and stabilize chronically elevated blood sugar levels. This targeted approach addresses the symptoms related to systemic imbalance. Ficonax is relevant for easing conditions characterized by systemic imbalance related to T2DM, as well as for conditions like Impaired Glucose Tolerance (IGT) and associated metabolic dysfunction in contexts such as Polycystic Ovary Syndrome (PCOS).

The core therapeutic benefit plays a role in managing and sustaining long-term glycemic control, which contributes to easing the overall symptom load and the long-term symptomatic burden associated with complications. The medication helps address symptom clusters that may become intense or disruptive, particularly those symptoms that interfere with daily functioning, such as excessive thirst, frequent urination, and physical discomfort.

“This supportive relief assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Systemic Imbalance

Ficonax is commonly used across conditions presenting with long-term, high blood sugar, and is considered relevant when supportive symptom management is appropriate. The medication assists with maintaining functional stability when symptoms of glucose dysregulation are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Ficonax?

Eligibility for Ficonax (Metformin) is strictly defined by official regulatory bodies based on specific health and age criteria. Use is contraindicated in patients with severe renal impairment (estimated eGFR below 30 mL/min/1.73 m^2), known hypersensitivity to the active ingredient, and any form of acute or chronic metabolic acidosis (e.g., diabetic ketoacidosis). The medicine is also prohibited during states of acute systemic instability, such as severe infection, shock, or acute/unstable congestive heart failure.

The drug is formally approved for use in adults and pediatric patients ge 10 years of age. However, treatment initiation is not recommended if the eGFR is between 30 and 45 mL/min/1.73 m^2. Older adults (ge 65) require more frequent monitoring of renal function. Use is generally avoided in cases of hepatic impairment. For women, use during pregnancy is typically managed with insulin, and Ficonax is not recommended during breastfeeding, as it is excreted into milk. Temporary discontinuation is required for patients undergoing surgery or radiological studies involving iodinated contrast agents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ficonax (Metformin) based on effects on renal clearance, metabolic potentiation, and additive glucose effects.

Documented Interaction Patterns

Procedural Restriction: Ficonax must be discontinued at the time of, or prior to, intravascular administration of iodinated contrast materials in specific populations (eGFR 30-60 mL/min/1.73 m^2, history of heart failure, alcoholism, or liver disease). The medicine must be withheld for 48 hours afterward until renal function is confirmed as normal.

Increased Plasma Exposure: Co-administration with cationic drugs like Cimetidine, Ranolazine, and Dolutegravir may reduce Ficonax clearance and increase its plasma concentration by competing for common renal tubular transport systems.

Additive Metabolic Risk: Concomitant use with Carbonic Anhydrase Inhibitors (e.g., Topiramate) or excessive intake of alcohol increases the risk for lactic acidosis. Alcohol potentiates the effect on lactate metabolism.

Pharmacodynamic Effects: Agents that increase blood glucose, such as Glucocorticoids and Thiazide Diuretics, can counteract the therapeutic effect of Ficonax. Conversely, co-administration with Insulin or Insulin Secretagogues may result in an additive blood-sugar-lowering effect, carrying a risk of hypoglycemia.

Population Note: The interaction risks are heightened in individuals with pre-existing conditions like Renal Impairment (eGFR < 60), Hepatic Impairment, or a history of Alcoholism.

Mechanism of Action

How Ficonax Works: Mechanism of Action

The mechanism of action for Ficonax (Metformin) is a multi-site approach focused on modulating physiological pathways related to glucose handling at the cellular level. Its effects are primarily driven through two key mechanistic domains.


1. Targeting the Liver’s Glucose Output

This domain describes how Ficonax initiates its action by mildly inhibiting Mitochondrial Complex I within liver cells. This molecular step activates the AMPK enzyme, a key cellular energy sensor, which leads to the downstream suppression of gluconeogenesis. This cascade results in the primary physiological effect of reducing hepatic glucose output.


2. Enhancing Peripheral Glucose Clearance

The activated AMPK pathway extends its influence outside the liver by modulating the cellular response to existing insulin in peripheral tissues like muscle and fat. This mechanism enhances the translocation of glucose transporters (GLUT4) to the cell surface, increasing the capacity for glucose uptake by cells. This action leads to the physiological consequence of increased peripheral glucose utilization and modulates systemic glucose concentrations.


This dual-action approach—limiting production and increasing clearance—achieves a systemic regulatory effect on circulating glucose.

Dosage and Administration Information

How Ficonax is Used: Official Administration Guidelines

Ficonax is administered via the oral route as a tablet and is generally prescribed as a long-term treatment. The precise way the medicine is used, including dosing and scheduling, is detailed in official documentation.


Official Dosing and Frequency

Formulation Starting Adult Dose Maximum Adult Daily Dose
Immediate-Release (IR) 500 mg twice daily OR 850 mg once daily 2550 mg, in divided doses
Extended-Release (ER) 500 mg once daily 2000 mg, once daily

Dose adjustments are made gradually, in increments of 500 mg, and occur no more frequently than every one to two weeks. The dose is adjusted based on individual control and tolerability. Pediatric patients 10 years of age and older may start at 500 mg twice daily, with a maximum dose of 2000 mg daily.


Contextual Instructions for Administration

Ficonax must be taken with or after meals to support proper use. Extended-release tablets are often recommended to be taken specifically with the evening meal. Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed.

Use of Ficonax is constrained by the patient's estimated glomerular filtration rate (eGFR), which is a measure of kidney function. The medication is officially contraindicated in patients with an eGFR below 30 mL/min/1.73 m^2. Starting Ficonax is not recommended for patients whose eGFR is between 30 and 45 mL/min/1.73 m^2. Additionally, temporary discontinuation of the medicine is required before or during certain surgical procedures and radiological studies involving iodinated contrast media.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ficonax

Evidence for Use in Type 2 Diabetes Mellitus

Research exploring Ficonax's evaluation in clinical trials for Type 2 Diabetes Mellitus includes large Randomized Controlled Trials (RCTs) and long-term observational follow-up studies in adults. Researchers measured changes in key blood sugar biomarkers, such as HbA1c and fasting glucose levels, and tracked long-term outcomes including all-cause mortality and major cardiovascular events. What remains uncertain is that some older studies can limit direct comparison, and reported observations on certain non-fatal cardiovascular events have been noted as variable.


Evidence for Use in Prediabetes (Impaired Glucose Tolerance)

Ficonax was studied for use in individuals with Impaired Glucose Tolerance (IGT) in large-scale RCTs. The main goal was to examine the frequency of participants progressing to a formal diagnosis of Type 2 Diabetes. Findings describe patterns regarding the rate of progression to T2DM and the reversion to normal glucose tolerance. When compared to intensive lifestyle changes, the findings were mixed. There is limited information for long-term outcomes concerning non-glycemic measures.


Research on Associated Metabolic Conditions (PCOS)

Research has examined Ficonax's use in women with Polycystic Ovary Syndrome (PCOS) and associated metabolic dysfunction in short-term RCTs. Researchers tracked metabolic biomarkers like insulin resistance indices and clinical indicators like menstrual cycle patterns. Due to high heterogeneity (differences in study design) and limited follow-up durations, the findings related to specific endocrine and reproductive outcomes have been noted as inconsistent.


Long-Term Evidence, Mortality, and Cardiovascular Follow-up

A significant portion of the evidence is derived from analyzing long-term observational follow-up studies and sub-analyses of major clinical trials. This research tracked all-cause mortality and cardiovascular-related death in individuals with Type 2 Diabetes. Findings regarding specific non-fatal events, such as non-fatal myocardial infarction and stroke, have been reported as mixed or less consistently documented.


Evidence in Specific Patient Populations

Ficonax was studied for use in several specific populations, particularly adolescents with Type 2 Diabetes, to evaluate changes in blood sugar biomarkers. Research involving older individuals examined how physiological strain or stress was assessed. Comprehensive long-term evidence in some specific elderly subgroups remains limited.


Key Limitations and Areas of Research Uncertainty

The scientific literature highlights that follow-up durations were limited for many trials outside of Type 2 Diabetes. Evidence quality varies across studies, particularly due to methodological differences in metabolic research. Finally, for some non-fatal cardiovascular outcomes, the findings were mixed, and data for certain groups remain insufficient.

Key Studies & References

  1. UK Prospective Diabetes Study (UKPDS) 34: A 10-year post-trial follow-up of patients with type 2 diabetes and the effect of intensive glucose control with metformin on outcomes
  2. The Current and Potential Therapeutic Use of Metformin—The Good Old Drug (Review highlighting UKPDS and long-term data)
  3. Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies (Addressing mixed MACE findings)

Frequently Asked Questions (FAQ)

Common questions about Ficonax (FAQ)


Q: What is the difference between Ficonax and [similar drug X]?

A: Official information classifies Ficonax (Metformin) as a Biguanide, which is a type of medicine that lowers blood sugar primarily by reducing the amount of glucose produced by the liver. This mechanism sets it apart from other diabetes medications, such as Sulfonylureas, which work by making the pancreas release more insulin. Regulatory documents describe the pharmacological distinctions of this medicine's class.


Q: Does Ficonax require regular blood tests?

A: Regulatory documents indicate that monitoring of kidney function (e.g., eGFR) is a requirement before initiating and during treatment. Periodic monitoring of hematological parameters, including Vitamin B12 levels, is also advised for patients on long-term use, as deficiency is associated with the medication.


Q: Is there a maximum time someone can be on Ficonax?

A: Ficonax is generally prescribed for long-term use in managing Type 2 Diabetes Mellitus. Official prescribing information does not define an absolute maximum duration of use. However, continued patient monitoring is recommended to ensure the drug remains appropriate and safety parameters are maintained over time.


Q: What does 'contraindication' mean in relation to Ficonax?

A: A contraindication is a specific condition or factor that officially serves as a reason to prohibit a medical treatment due to the potential harm it poses. For Ficonax, contraindications listed in regulatory materials include having severe kidney impairment, any known hypersensitivity (severe allergy) to the active ingredient, or certain forms of metabolic acidosis.


Q: Is Ficonax considered a 'high-risk' medication?

A: Ficonax is widely used as a first-line therapy. However, the official label includes a Boxed Warning for Lactic Acidosis. This is described as a rare but serious metabolic complication. Regulatory documents mandate strict patient criteria and monitoring to mitigate this risk, which governs its use.


Q: How long does it usually take to notice any effect from Ficonax?

A: Official patient information indicates that Ficonax typically starts to lower blood sugar levels within the first week of beginning use. However, regulatory information suggests that it may take about two to three months of consistent use for the medication to achieve its full therapeutic effect on overall glucose control.


Q: Does Ficonax have a generic version available?

A: Yes. Ficonax is the brand name for the active ingredient, Metformin Hydrochloride. Metformin is an established compound that is widely available from various manufacturers as a generic medication.


Q: What should I do if I miss a dose of Ficonax?

A: Patient education materials describe the approach if a dose is missed: to take the dose when remembered. However, if it is nearly time for the next scheduled dose, the recommended approach involves skipping the missed dose and taking only the next usual dose. Official guidance advises against taking a double dose.


Q: Are there any common over-the-counter pain relievers that interact with Ficonax?

A: Official documentation cautions against co-administration of Ficonax and drugs that may impair kidney function. Interference with the kidneys' ability to clear Ficonax can increase the risk of Lactic Acidosis. Official documents specify certain drug classes that may pose this risk.


Q: Why do some people say Ficonax makes them feel dizzy?

A: While dizziness is not typically listed as a common side effect of Ficonax alone, it can be a symptom of a serious complication like Lactic Acidosis. It can also be a sign of hypoglycemia (very low blood sugar) when Ficonax is used alongside insulin or other medications that stimulate insulin release.


Q: Can Ficonax affect my ability to drive?

A: Official product information, particularly when Ficonax is used in combination with insulin or insulin secretagogues, often includes a caution about hypoglycemia (low blood sugar). The potential for low blood sugar may result in impaired concentration and coordination, which is an important consideration for tasks such as driving or operating machinery.


Q: How common are skin reactions or rash with Ficonax?

A: Skin rash or generalized allergic reactions are not listed among the common or very common side effects in regulatory documents. However, Ficonax is officially contraindicated in any patient with a known history of hypersensitivity (severe allergic reaction) to the active substance, Metformin.


Q: Does Ficonax affect appetite or cause weight changes?

A: A loss of appetite is listed as a common side effect, especially when treatment is first initiated. Furthermore, official safety documents note that a decreased appetite can be one of the early symptoms that accompany the onset of the serious side effect, Lactic Acidosis.


Q: What should I look for if I think I'm having an allergic reaction to Ficonax?

A: Official regulatory materials describe the serious symptoms associated with a severe allergic reaction, which may include swelling of the face, eyes, lips, or tongue, or difficulty breathing. The rapid development of an itchy skin rash spreading over the body is also noted.


Q: Are there any known interactions between Ficonax and birth control pills?

A: Official drug interaction information notes that certain oral contraceptives, such as those containing levonorgestrel, may interfere with blood sugar control. This outcome could potentially reduce the blood-sugar-lowering effectiveness of Ficonax. When co-administered, monitoring of blood sugar levels may be warranted.


Q: Why is Ficonax available only by prescription?

A: Ficonax is required to be prescription-only primarily due to the seriousness of the underlying condition it treats (Type 2 Diabetes) and the need for ongoing medical oversight. The essential requirement for periodic kidney function monitoring and the rare, but serious, risk of Lactic Acidosis necessitates physician supervision.


Q: How quickly does Ficonax leave the body after the last use?

A: Official Clinical Pharmacology data states that the time it takes for the concentration of Ficonax (Metformin) to be halved in the blood—known as the elimination half-life—is approximately 6.2 hours. In individuals with normal kidney function, it generally takes about four days for the drug to be almost entirely cleared from the body.


Q: Are there common signs that Ficonax is not working for me?

A: The effectiveness of Ficonax is monitored by checking blood sugar biomarkers, most importantly Fasting Blood Glucose and HbA 1c levels. If the measured levels of these biomarkers remain consistently outside established therapeutic goals, this may suggest that the medicine is not providing sufficient glucose control.

How should Ficonax be stored and disposed of?

How to Store and Dispose of Ficonax (Metformin Hydrochloride) Tablets

The storage and disposal of Ficonax must strictly follow official regulatory guidelines to maintain stability and ensure safety.


Storage Requirements

Requirement Condition (Official Regulatory Basis)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect the tablets from moisture, excessive heat, and light.
Container Keep the product in the original container, tightly closed.
Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Any unused or expired Ficonax must be disposed of in accordance with local pharmaceutical waste regulations. The medication must not be poured down a drain or flushed down the toilet unless specifically authorized. Where available, return the unused product to an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ficonax found in:

A-Z Index: